1 blood donation from one donor (1) is enough for Cynata's Cymerus manufacturing platform - "at the current processing scale - [...] to generate 2.9 × 10^15 MSCs, or 29 million clinical doses (each containing 1 × 10^8 MSCs)" according to our published paper in nature medicine. (2)
2 AUD per share takeover offer proposed (indicative, non-binding) by Sumitomo Dainippon Pharma in July 2019 valued Cynata at A$202 at the time (3). Cynata announced in October 2019 that these negotiations have ceased as "it had been 'unable to reach agreement on terms to its satisfaction". (4)
3 days, the representative speed of wound healing, was used as primary outcome measure to compare the extent of re-epithelialisation (skin restoration) in a pre-clinical model of diabetic wounds, after a polymer-coated dressing seeded with MSCs from different sources was applied to the wound surface. "Dressings seeded with Cymerus MSCs resulted in significantly greater re-epithelialisation after three days (86 percent) than dressings seeded with commercially available bone marrow-derived MSCs (51 percent). MSCs derived from dental pulp, gingival fibroblasts and bone chips resulted in re-epithelialisation of 68, 80 and 91 percent, respectively, after three days. These results suggest that the most effective cell types for this application are Cymerus MSCs or MSCs derived from gingival fibroblasts or bone chips. However, the gingival fibroblast- and bone chipderived MSCs were produced in an academic laboratory under non-GMP conditions, and there are major challenges associated with producing clinical-grade cells from those sources at commercial scale." (5)
004 - that's the number of our product currently trialed in a 24 month 440-patient Phase 3 Australian based clinical trial for patients with osteoarthritis of the knee. The "trial [is] being sponsored by the University of Sydney and funded by an Australian Government National Health and Medical Research Council (NHMRC) competitive Project Grant in addition to in-kind contributions from participating institutions." (6)
5 % of our SOI, that's the investment size of 3 companies/funds/insitutions that currently hold shares in excess of: Fidelity International, FujiFilm Corporation and Bioscience Managers.
6 active trials we could potentially have recruiting by years end: OA, ARDS, DFU, Renal Transplantation, IPF and GvHD.
7 ,615,374 - the US patent number including another number of patents licensed/owned/in process around the world covers the "patented process of generating cell-based products from intermediate cells, known as mesenchymoangioblasts (MCAs), which in turn are derived from induced pluripotent stem cells (iPSCs). This technology was originally developed at the University of Wisconsin-Madison (UWM), a world-renowned leader in stem cell research." (1)
8 years have gone by since Cynata's backdoor listing via a failed "backdoor" related company (Ecoquest), signing an exclusive license agreement with WARF for Cynata Inc.'s Cymerus iPSC-MSC technology. (7)
9 out of 15 patients or 60%, that's the two year survival rate of patients in our P1 clinical trial in SR-aGvHD who received between 1 (Cohort A) -2 (Cohort B) million cells / kg bodyweight on 2 occasions. The achieved survival rate " compares favourably with previously published outcomes: an overall survival rate of just 17% after two years has been reported in patients with steroid-resistant acute GvHD who received standard of care treatment". (8)
10 % royalty is what Cynata can expect from licensing its lead product CYP-001 in GvHD to FujiFilm in 2019, with an upfront payment of US$3m and potential milestone payments of up to US43m. (9)
(20min delay)